If you live in Indiana and are considering compounded semaglutide or compounded tirzepatide, this page is meant to save you a few hours of tab-hopping. It covers how access actually works here, what Indiana law says about telehealth prescribing and pharmacy compounding, including a new state law aimed squarely at compounded GLP-1s, what treatment costs at Gentle Health, and how those prices compare with other providers serving the state, using each provider’s own public pages as the source. One disclosure up front: this site is operated by Gentle Health, a telehealth practice that offers compounded GLP-1 medications, so we have an interest in the subject. We have tried to keep the facts checkable anyway. Every price and rule cited below links to its source, and anything we could not verify is flagged rather than guessed at.
How compounded GLP-1 access works in Indiana
Indiana permits prescribing through telehealth without a prior in-person examination for non-controlled medications, provided the prescriber meets the same standard of care that would apply in an office visit (IC 25-1-9.5-7). Semaglutide and tirzepatide are not controlled substances, so the stricter rules Indiana attaches to opioids and other controlled drugs do not apply. That is what makes the telehealth model workable from Evansville to Elkhart.
At Gentle Health, the process looks like this:
- Health intake. You complete a detailed medical history online: current medications, prior conditions, relevant labs if you have them, and your goals.
- Medical evaluation. Care at Gentle Health is provided by James Simmons, MD, who is licensed to practice in Indiana through the Interstate Medical Licensure Compact (license 01100922A, state board record), an agreement among more than 40 states that lets qualified physicians hold full licenses across member states, Indiana included (imlcc.com). Dr. Simmons reviews your intake and evaluates whether treatment is medically appropriate. Not everyone is approved.
- Prescription and fulfillment. If Dr. Simmons prescribes treatment, the prescription goes to a licensed compounding pharmacy, and the medication ships to your Indiana address.
- Ongoing care. Dosing is reviewed and adjusted over time, and you can reach out between refills with questions or side-effect concerns.
Two Indiana-specific details worth knowing about that second step. First, Indiana law requires a provider-patient relationship to be established before a prescriber issues a prescription via telehealth; a proper intake and evaluation is how that relationship is formed (IC 25-1-9.5-13). Second, a practitioner who is physically located outside Indiana and treats Indiana patients by telehealth submits to the jurisdiction of Indiana’s licensing boards and courts (IC 25-1-9.5-9). In plain terms: an out-of-state telehealth physician treating you in Indiana must hold an Indiana license and answer to Indiana regulators. That is the arrangement Dr. Simmons practices under, via the Compact.
The whole arrangement is cash-pay. There is no insurance paperwork because Gentle Health does not bill insurance.
Indiana rules worth knowing
Indiana has one of the more clearly written telehealth statutes in the country, and, as of this year, one of the first state laws aimed specifically at compounded GLP-1s. A few points worth understanding before you sign up with anyone, including us:
Telehealth prescribing is expressly legal, with guardrails. Indiana Code chapter 25-1-9.5 governs telehealth services and prescriptions (full chapter). A prescriber delivering care through telehealth is held to the same standard of appropriate practice as in-person care (IC 25-1-9.5-7), and may issue a prescription without a prior in-person examination if the standard of care is satisfied, the prescription is within the prescriber’s scope of practice, and the medication is not an opioid (IC 25-1-9.5-8). The statute also expects the prescriber, with the patient’s consent, to notify the patient’s primary care provider of prescriptions issued and to give the patient a visit summary. The state’s Professional Licensing Agency maintains a telehealth resource page if you want the official overview (in.gov/pla).
A provider-patient relationship is required first. Indiana does not allow a prescription to be issued to someone in the state via telehealth unless a provider-patient relationship has been established (IC 25-1-9.5-13). A questionnaire that no clinician meaningfully reviews does not establish one. If a website will sell you a GLP-1 without any real evaluation, that is a signal to walk away, whatever the price.
Indiana passed a GLP-1 compounding law this year. Senate Bill 282, authored by Senators Ed Charbonneau and Justin Busch, moved through the 2026 session with lopsided votes (47-1 in the Senate) and was signed by Governor Mike Braun on March 5, 2026 (bill page; Lengea Law; The Indiana Lawyer). The law requires pharmacies that compound GLP-1 medications for Indiana patients to comply with the federal Food, Drug, and Cosmetic Act’s compounding provisions, including that compounding be performed by a state-licensed pharmacist, and it gives the Indiana Board of Pharmacy authority to investigate and enforce compliance. It also requires medical spas that furnish GLP-1s to register with the Medical Licensing Board of Indiana. The compounding and drug-sourcing provisions took effect July 1, 2026; the medical spa registration framework phases in by January 1, 2027 (AmSpa summary). As of this writing (checked July 30, 2026), the Indiana Board of Pharmacy has not published implementation guidance specific to SB 282 on its public pages; the statute itself and the sources above are the controlling references.
What SB 282 means for patients, practically. The law targets the supply side: it holds compounding pharmacies and med spas to federal standards and gives the Board of Pharmacy teeth to enforce them. It does not ban compounded GLP-1s prescribed for an individual patient by a licensed prescriber and prepared by a properly licensed pharmacy. If anything, it gives Indiana patients a sharper question to ask any provider: is the pharmacy filling this prescription licensed and operating within section 503A of the Food, Drug, and Cosmetic Act? Under 503A, a licensed pharmacy may compound a medication for an individual patient pursuant to a valid prescription, subject to restrictions, including limits on compounding what amounts to a copy of a commercially available drug. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, which narrowed the circumstances under which compounding is permitted, and the agency maintains a page describing its concerns and current policy (FDA). Compounded medications are not FDA-approved, and any provider who tells you otherwise is not being straight with you.
None of this is legal advice; it is a plain-language summary of public sources, each linked above so you can read them yourself.
Compounded semaglutide in Indiana
Semaglutide is a GLP-1 receptor agonist, a class of medications that mimic a naturally occurring gut hormone involved in appetite regulation and blood sugar control. Compounded semaglutide is a version of that molecule prepared by a licensed compounding pharmacy for an individual patient, based on a prescription. It is prescribed at the discretion of the evaluating physician when a compounded preparation is clinically appropriate for that specific patient. It is not an FDA-approved product, it does not go through the FDA’s premarket review, and results from clinical trials of FDA-approved semaglutide products should not be assumed to apply to it.
Gentle Health offers compounded semaglutide in two forms for Indiana patients:
- Oral compounded semaglutide: starting at $112 per month. Taken daily, no needles involved.
- Injectable compounded semaglutide: starting at $135 per month. A once-weekly subcutaneous injection, the format most people picture when they think of GLP-1 treatment.
Both prices are cash-pay and dose-tiered, and include the medical care described above: evaluation by James Simmons, MD, the prescription if treatment is appropriate, the medication itself, and ongoing dosing review. There is no separate membership fee, no intro rate that resets to a higher number after the first month, and no insurance involvement. As the comparison table below shows, the intro-price-then-increase structure is common in this market, so it is worth reading any provider’s fine print, including ours.
Whether semaglutide is appropriate for you is a medical question, not a marketing one. Side effects, most commonly gastrointestinal, are real, and treatment is subject to medical evaluation and is not approved for every applicant.
Compounded tirzepatide in Indiana
Tirzepatide works on two receptors rather than one: GLP-1 and GIP, a second gut hormone involved in metabolic regulation. It is the newer of the two molecules, and cash prices for it run higher than semaglutide almost everywhere it is offered. That gap is easy to see in the Indiana market: the compounded tirzepatide programs in the table below run from $169 to around $300 or more per month, depending on the provider and format.
Gentle Health offers injectable compounded tirzepatide starting at $169 per month for Indiana patients. Like the semaglutide programs, the price is cash-pay and dose-tiered, and it covers the evaluation by James Simmons, MD, the prescription when appropriate, the compounded medication from a licensed pharmacy, and ongoing care. Once-weekly subcutaneous injection.
The same caveats apply, and they are worth repeating rather than burying: compounded tirzepatide is not an FDA-approved product. It is prepared for an individual patient by a licensed compounding pharmacy under section 503A when the prescribing physician determines a compounded preparation is appropriate for that patient. Trial data generated for FDA-approved tirzepatide products describe those products, not compounded preparations. And no medication in this class is a substitute for the unglamorous fundamentals of nutrition, movement, and sleep; it is a tool that works alongside them for appropriate patients.
If you are weighing semaglutide against tirzepatide, that choice belongs in the medical evaluation, where your history, tolerability considerations, and budget can all be on the table at once.
Provider options in Indiana: comparison table
Methodology: rows are listed alphabetically; prices were taken only from each provider’s own public website, on the verification date shown in each row (2026-07-27 to 2026-07-30), and where a provider does not publish pricing we write “See site” rather than estimating. Gentle Health operates this site and appears in the table on the same terms as everyone else.
| Provider | Care model | Compounded semaglutide (cash/mo) | Compounded tirzepatide (cash/mo) | Serves Indiana | Insurance | Source |
|---|---|---|---|---|---|---|
| Gentle Health | Telehealth; care by James Simmons, MD | From $112 (oral) / From $135 (injectable) | From $169 (injectable) | Yes | Cash-pay only; insurance not billed | Gentle Health pricing (verified 2026-07-30) |
| Henry Meds | Telehealth; medication plus provider access | $247 after intro month (weekly injectable) | $349 after intro month (daily oral tablet) | See site | Not required; cash-pay | henrymeds.com (verified 2026-07-30) |
| Mochi Health | Telehealth; membership plus medication billed separately | From $99 medication + $79/mo membership ($39 first month) | From $199 medication + $79/mo membership | Yes (site locations list) | See site | joinmochi.com (verified 2026-07-27) |
| Monarch Medicine | In-person clinic, Carmel, IN; physician-supervised, medication shipped for home use | $300 (4 weekly injections) | $300 (4 weekly injections) | Yes (Carmel; in-person visits required) | Medication is self-pay; initial evaluation and labs billed to insurance | monarchmedicine.org (verified 2026-07-27) |
| OrderlyMeds | Telehealth; all-inclusive plans | $149 after starter (from $74 starter) | $299 after starter (from $149 starter) | Yes (site states providers licensed in all 50 states) | Not required; cash-pay | orderlymeds.com (verified 2026-07-27) |
A few reading notes. Intro and starter prices reset upward after the promotional period, so the “thereafter” number is usually the one to budget around. Membership-model providers bill the membership whether or not medication ships that month; check each provider’s terms. Monarch’s model mixes billing types: the medication is a flat self-pay fee while the evaluation and lab work run through insurance, which can be a plus or a complication depending on your plan. Some providers also sell FDA-approved brand products at substantially higher cash prices; those are out of scope for this table, which compares compounded programs only. Formats differ too: one provider’s tirzepatide offering above is an oral tablet rather than an injection, which matters if you have a preference. Prices change often in this market. If you spot a stale number, the source links are there to check, and we will correct promptly.
FAQ: compounded GLP-1s in Indiana
Is compounded semaglutide legal in Indiana? Yes, within limits. Indiana law permits prescribing via telehealth once a provider-patient relationship is established (IC 25-1-9.5-13), and federal law permits a licensed pharmacy to compound medication for an individual patient under section 503A when a prescriber determines it is appropriate for that patient. Indiana’s SB 282, effective July 1, 2026, adds state-level enforcement: pharmacies compounding GLP-1s for Indiana patients must comply with federal compounding standards, and the Indiana Board of Pharmacy can investigate violations. Compounded medications are not FDA-approved. Buying from a licensed pharmacy pursuant to a physician’s prescription is the lawful path; buying research-grade peptides online without a prescription is not.
Do I need an in-person doctor visit to get a prescription in Indiana? No. Indiana allows a prescriber to issue a prescription through telehealth without a prior in-person examination, as long as the standard of care is met, the prescription is within the prescriber’s scope of practice, and the medication is not an opioid (IC 25-1-9.5-8). GLP-1 medications are not controlled substances, so the telehealth route is available for them.
What does Indiana’s new SB 282 mean for me as a patient? Mostly that the pharmacy side of your treatment is under closer state supervision. SB 282 requires compounders serving Indiana patients to follow federal Food, Drug, and Cosmetic Act standards and gives the Board of Pharmacy enforcement authority; med spas that furnish GLP-1s must register with the Medical Licensing Board. It does not prohibit individually prescribed compounded GLP-1s. A reasonable takeaway: ask any provider, including us, which pharmacy fills the prescription and confirm it is licensed.
Who provides the medical care at Gentle Health for Indiana patients? James Simmons, MD, who holds an Indiana license through the Interstate Medical Licensure Compact. He conducts the evaluation, decides whether treatment is appropriate, prescribes when it is, and manages dosing over time. There is no rotating cast; your care stays with one physician, and as an Indiana-licensed prescriber he is subject to Indiana’s licensing boards like any local doctor (IC 25-1-9.5-9). His Indiana plan details and current dose tiers are on our Indiana page, along with local pages for Noblesville, South Bend and Fishers; it is the same physician and the same published price on every one.
Does Gentle Health sell Ozempic, Wegovy, Mounjaro, or Zepbound? No. Gentle Health does not sell Ozempic, Wegovy, Mounjaro, or Zepbound. We offer compounded semaglutide and tirzepatide, which are different products. Gentle Health is not affiliated with, or endorsed by, Novo Nordisk or Eli Lilly, the manufacturers of those FDA-approved products. If you want a brand product, your primary care physician or a provider that dispenses them is the right route.
Will my insurance or Indiana Medicaid cover this? Gentle Health is cash-pay and does not bill insurance; the dose-tier prices include medication and care without a separate membership fee. Insurance coverage for compounded medications in general is uncommon, and coverage rules for GLP-1s under Indiana plans vary and change; check directly with your plan if coverage matters to your decision.
What should compounded GLP-1 treatment actually cost in Indiana? Based on the public pricing in the table above, ongoing monthly cash prices from providers serving Indiana currently run from roughly $112 to $349 depending on molecule, format, and provider, before intro discounts, and before any membership fees that bill separately. Whatever you are quoted, confirm three things: the price after any intro period, whether membership fees are separate from medication, and whether medical care and follow-up are included.
Current Gentle Health dose tiers and pricing
Gentle Health pricing depends on the dose tier prescribed by your clinician. Current monthly prices are:
Oral compounded semaglutide
| Tier | Daily dose | Monthly price |
|---|---|---|
| Starting | 2-4 mg/day | $112/mo |
| Medium | >4-8 mg/day | $189/mo |
| High dose | >8-12 mg/day | $258/mo |
Injectable compounded semaglutide
| Tier | Weekly dose | Monthly price |
|---|---|---|
| Starting | 0.24-0.48 mg/wk | $135/mo |
| Medium | >0.48-1.2 mg/wk | $159/mo |
| High dose | >1.2-2.4 mg/wk | $199/mo |
Injectable compounded tirzepatide
| Tier | Weekly dose | Monthly price |
|---|---|---|
| Starting | 2.5-5 mg/wk | $169/mo |
| Medium | >5-10 mg/wk | $219/mo |
| High dose | >10-15 mg/wk | $269/mo |
Medication, the initial review by a licensed clinician, video visits and messaging, and overnight refrigerated shipping are included. There is no separate membership fee, and HSA and FSA cards are accepted. Your clinician determines the appropriate medication and dose; the monthly price changes if the prescribed dose moves into a different tier.
Gentle Health serves patients across a growing multistate footprint through clinicians licensed in each patient’s jurisdiction, including Indiana.
Reviewed by James Simmons, MD
Compounded medications are not FDA-approved. Treatment subject to medical evaluation.